Turkish Isolated Coronary Ectasia Registry: The T-ICE Registry

Turkish Isolated Coronary Ectasia Prospective Cohort Study: the T-ICE Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05897333

Acronym

T-ICE

Enrollment

3000

Registered

2023-06-09

Start date

2022-03-15

Completion date

2032-03-15

Last updated

2023-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The T-ICE study is a prospective, observational study aiming to have information about the treatment and long-term prognosis of patients with isolated coronary artery ectasia.

Detailed description

Coronary artery ectasia is a localized or diffuse enlargement of the coronary artery lumen ≥1.5-2 times relative to the normal segment. It is often associated with coronary artery stenosis. Some patients have coronary artery ectasia without stenosis. This condition is called as isolated coronary artery ectasia. There is data other than retrospective studies with a small number of cases on the clinical significance, prognosis and treatment of isolated coronary ectasia in patients with or without acute coronary syndrome. Therefore, the treatment of patients with isolated coronary ectasia is not evidence-based and is based on the clinical judgment of physicians. The aim of this prospective observational study is to evaluate the treatment and prognosis of the isolated coronary artery ectasia. The second aim is to compare the prognosis of isolated coronary ectasia with the coronary artery disease.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Inclusion criteria

* Isolated coronary artery ectasia (without ≥20% stenosis in any coronary artery ≥2 mm in diameter). * All patients with isolated coronary ectasia with or without acute coronary syndrome will be included. * Patients aged ≥18 years. * Patients with discrete coronary artery aneurysm will be included.

Exclusion criteria

* Life expectancy \<24 months * Patients with ≥20% stenosis in a vessel ≥2 mm in diameter.

Design outcomes

Primary

Measure	Time frame	Description
Major adverse cardiovascular and cerebrovascular events	Five years	A composite endpoint of death, myocardial infarction, unstable angina, stroke, and coronary revascularization.

Secondary

Measure	Time frame	Description
Major adverse cardiovascular events	Five years	A composite endpoint of cardiovascular death, myocardial infarction, unstable angina, and coronary revascularization.

Countries

Turkey (Türkiye)

Contacts

Primary ContactAdnan Abaci

abaci@gazi.edu.tr+903122025631

Backup ContactEmrullah Kızıltunc

e.kiziltunc@gmail.com+903122025629

Outcome results